StonvexLoading…
StonvexStonvexStonvexCore line items from CTVA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $17.40B | $16.91B | $17.23B | $17.45B |
Operating Income | $1.69B | $1.27B | $1.09B | $1.43B |
Net Income | $1.09B | $907.00M | $735.00M | $1.15B |
EPS (Diluted) | $1.60 | $1.30 | $1.03 | $1.58 |
Total Assets | $42.84B | $40.83B | $43.00B | $42.62B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $4.52B | $3.11B | $2.64B | $3.19B |
Free Cash Flow OCF − CapEx | $2.81B | $1.55B | $1.17B | $267.00M |
Shares Outstanding | 672.16M | 685.60M | 701.26M | 713.42M |